Patents by Inventor Gideon Schreiber

Gideon Schreiber has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS OF TARGETING AGENTS TO ACE2 RECEPTORS
    Publication number: 20240009315
    Abstract: Particles having an ACE2 targeting moiety attached to an outer surface thereof are disclosed herein. The ACE2 targeting moiety comprises a polypeptide comprising an amino acid sequence of SARS CoV-2 receptor-binding domain (RBD), wherein said amino acid sequence comprises a modification at position 358 and at least two additional modifications at two positions selected from the group consisting of 484, 498 and 501. Uses of the particles for treatment and diagnosis of diseases are also disclosed.
    Type: Application
    Filed: August 2, 2023
    Publication date: January 11, 2024
    Applicant: Yeda Research and Development Co. Ltd.
    Inventors: Gideon SCHREIBER, Jiri ZAHRADNIK, Amnon BAR-SHIR, Yinon RUDICH, Andrea GALISOVA
  • METHODS AND COMPOSITIONS FOR TREATING CORONAVIRAL INFECTIONS
    Publication number: 20230263884
    Abstract: A polypeptide comprising an amino acid sequence of SARS CoV-2 receptor-binding domain (RBD) is disclosed, wherein said amino acid sequence comprises a modification at position 358 and at least two additional modifications at two positions selected from the group consisting of 484, 498 and 501, wherein the polypeptide binds soluble, monomeric angiotensin-converting enzyme 2 (ACE2) receptor. Uses thereof are further disclosed.
    Type: Application
    Filed: March 16, 2023
    Publication date: August 24, 2023
    Applicant: Yeda Research and Development Co. Ltd.
    Inventors: Gideon SCHREIBER, Jiri ZAHRADNIK, Yinon RUDICH
  • Type I Interferon Antagonists
    Publication number: 20110224407
    Abstract: Disclosed in certain embodiments is a method of preparing a Type 1 interferon antagonist comprising modifying a Type 1 interferon at the site of interaction with the interferon receptor subunit IFNAR-1 such that the binding affinity of the interferon to the IFNAR-1 subunit is reduced as compared to the native interferon, and corresponding compositions and methods of treatment thereof.
    Type: Application
    Filed: September 9, 2009
    Publication date: September 15, 2011
    Applicants: UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY, YEDA RESEARCH AND DEVELOPMENT CO., LTD.
    Inventors: Jerome Langer, Gideon Schreiber
  • IFNAR2 MUTANTS, THEIR PRODUCTION AND USE
    Publication number: 20100239530
    Abstract: The present invention relates to mutant polypeptides of the beta chain of the type I IFN receptor (IFNAR2 mutant) with enhanced affinity for IFN? as compared to the wild type protein for prolonging the effect of IFN? in vivo.
    Type: Application
    Filed: May 26, 2010
    Publication date: September 23, 2010
    Applicant: YEDA RESEARCH AND DEVELOPMENT CO., LTD. AT WEIZMANN INSTITUTE OF SCIENCE
    Inventor: GIDEON SCHREIBER
  • IFNAR2 mutants, their production and use
    Patent number: 7749735
    Abstract: The present invention relates to mutant polypeptides of the beta chain of the type I IFN receptor (IFNAR2 mutant) with enhanced affinity for IFN? as compared to the wild type protein for prolonging the effect of IFN? in vivo.
    Type: Grant
    Filed: December 31, 2002
    Date of Patent: July 6, 2010
    Assignee: Yeda Research and Development Co., Ltd.
    Inventor: Gideon Schreiber
  • Ifnar2 mutants, their production and use
    Publication number: 20050164185
    Abstract: The present invention relates to mutant polypeptides of the beta chain of the type I IFN receptor (IFNAR2 mutant) with enhanced affinity for IFN? as compared to the wild type protein for prolonging the effect of IFN? in vivo.
    Type: Application
    Filed: December 31, 2002
    Publication date: July 28, 2005
    Inventor: Gideon Schreiber